A patient with progressive prolymphocytic leukemia (PLL) received an allogeneic stem cell transplant using a reduced intensity conditioning regimen to avoid prohibitive toxicities. Early in the post-tranplant period, a high donor-derived CD8
Prolymphocytic leukemia (PLL) is an aggressive subtype of chronic lymphocytic leukemia (CLL), of which it represents 10% of cases. The prognosis is generally poor, particularly in patients with refractory disease. Here, we report a case of refractory primary PLL successfully treated using a reduced intensity conditioning regimen followed by allogeneic peripheral blood stem cell transplantation.
Case report
A 53-year-old Caucasian female was diagnosed as having PLL in March 1999. Her clinical picture was characterized by polyadenopathies and splenomegaly. Peripheral cell counts showed hyperlymphocytosis (Ͼ150 × 10 9 /l) and anemia (8.8 g/dl), while peripheral immunophenotyping was consistent with a monoclonal proliferation of CD5/CD19/CD20/FMC7/sIg-positive B cells. A bone marrow smear also suggested PLL and cytogenetic analysis showed a complex karyotype (45, X, −X, add 11, +8, del 11q23, add 14q, der 18, add 21q). The patient was initially treated with fludarabine (25 mg/m 2 /day for 5 days), which led to a slight transient decrease in lymphocytosis. Sub- sequently, in April 1999, she received four CHOP courses (cyclophosphamide, vincristine, doxorubicin and prednisone) with disease progression. In August 1999, she was given one ESHAP course (etoposide, high-dose cytarabine and methylprednisone) without any effect on the lymphocytosis and splenomegaly. A 9-weekly chemotherapy schedule with daunorubicin and prednisone was started in September 1999, followed by daily oral 6-mercaptopurine, which led to stabilization of the lymphocytosis (about 25 × 10 9 /l). In November 1999, four doses of rituximab (375 mg/m 2 /week) markedly reduced the lymphocytosis for a short period. In February 2000, an increase in her peripheral lymphocyte count was observed without adenopathies or splenomegaly (pre-transplant spleen diameter 13 cm) and she received a minimally conditioned bone marrow transplant from her HLA-identical brother. The conditioning regimen consisted of fludarabine (25 mg/m 2 /day × 5 days) and cyclophosphamide (60 mg/kg/day × 2 days). The donor was mobilized with G-CSF (10 g/kg/day) and 4.7 × 10 6 CD34 + cells were harvested on day +5. Cyclosporine plus a 'short' methotrexate course were used for acute GVHD prophylaxis. The transplant was complicated by mild veno-occlusive disease, hemorrhagic cystitis and gram-positive bacteriemia. After an initial increase in neutrophils (day +20: WBC 4.2 × 10 9 /l, neutrophils 2.8 × 10 9 /l and lymphocytes 0.4 × 10 9 /l), a progressive increase in lymphocytes was observed in association with a reduction in neutrophils (day +24: WBC 1.7 × 10 9 /l, neutrophils 0.4 × 10 9 /l, lymphocytes 0.9 × 10 9 /l). pp65 antigenemia analysis did not reveal cytomegalovirus reactivation. Immunophenotyping showed CD8-positive lymphocytes, in the absence of B cell proliferation. Standard cytogenetic chimeric analysis showed complete donor-derived hematolymphopoiesis. G-CSF was started and led to a rapid increase in neutrophils. Mild acute cutaneous GVHD (grade I) was observed on day +23, but it regressed without treatment.
As of February 2001 (day +376), the patient is in complete remission (as determined by marrow morphology, immunophenotype and standard cytogenetics), with complete chimerism (determined by standard cytogenetics and FISH), and without chronic GVHD.
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Discussion
Alkylating agent-based chemotherapies have led to a poor response rate and survival in PLL patients. 1 Response rates are higher with lymphoma-like regimens, but these offer no improvement in terms of survival. Encouraging results have been obtained using purine analogues 2 but, although they lead to a higher rate of complete remission, long-term survival remains poor. 3 It has been shown that allogeneic stem cell transplantation is effective in the treatment of relapsing or progressive CLL but, when myeloablative conditioning regimens are used, treatment-related mortality is considerable. 4 Mehta et al 5 described a refractory PLL patient who received an HLA-related allogeneic bone marrow transplantation after a conventional regimen of total body irradiation plus melphalan; malignant lymphocytes disappeared with both immunosuppressive tapering and acute GVHD onset. However, this patient died of uncontrolled chronic GVHD. 5 Similary, a graft-versus-leukemia (GVL) effect has been observed after donor lymphocyte infusion and chronic GVHD in refractory CLL. 6 A number of recent studies have shown the feasibility of reducing the intensity of conditioning regimens without compromising hematopoietic recovery, and establishing complete or mixed chimeras. 7, 8 Most of these studies have used fludarabine-based conditioning regimens, but GVHD prophylaxis is frequently different in terms of drugs used and duration of therapy. Allogeneic peripheral stem cells have been used in almost all patients.
Khouri et al 9 used a non-myeloablative conditioning regimen followed by the grafting of peripheral blood stem cells from HLA-identical siblings in eight patients with relapsed/refractory CLL and in seven low-grade non-Hodgkin's lymphoma: eight patients achieved complete remission after transplantation. In these cases the occurrence of a GVL effect was observed at the time of GVHD or after immunosuppression tapering or donor lymphocyte infusion (DLI) and cGVHD. Furthermore, the GVHD was severe and fatal. It is worth noting that these authors used high-dose TBI-based regimens, which may have contributed to GVHD.
We report data on the feasibility and efficacy of a reduced intensity conditioning regimen before allogeneic peripheral blood stem cell transplantation in a patient with refractory primary PLL. The patient had been heavily pretreated and was in disease progression before transplantation. In this heavily pre-treated patient, the nonmyeloablative regimen was extremely well tolerated: only grade I acute GVHD was observed during hospitalization and no signs of chronic GVHD were detected during follow-up. Complete chimerism was quickly obtained. Immunosuppression was tapered slowly up to day +180, and so a GVL effect may have been active even in the absence of clinically evident GVHD and with immunosuppressive therapy. Furthermore, a GVL reaction alone could explain the disappearance of the prolymphocytes as it is unlikely that the drugs used in the conditioning regimen would lead to a long-term relapse-free outcome. Indeed, the increase in donor-derived CD8 + lymphocytes could be the biological evidence of GVL which seems to have been effective after minimally conditioned allogeneic stem cell transplantation in this patient with refractory PLL.
